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ORIGINAL ARTICLE
Pregnancy and contraceptive use among women
participating in an HIV prevention trial in Tanzania
Aderonke Odutola,1 Kathy Baisley,1 Richard J Hayes,1 Mary Rusizoka,2 Clare Tanton,1
Helen A Weiss,1 John Changalucha,3 David A Ross,1 Deborah Watson-Jones1,2,4
ABSTRACT
Objectives Information on pregnancy rates and factors
associated with pregnancy and contraceptive use is
important for clinical trials in women in sub-Saharan
Africa where withdrawal of investigational products may
be required in the event of pregnancy with a consequent
effect on sample size and trial power.
Methods A prospective cohort analysis of pregnancy
and contraceptive use was conducted in Tanzanian
women enrolled in a randomised placebo-controlled trial
of herpes simplex virus-suppressive therapy with
acyclovir to measure the effect on HIV incidence in HIV-
negative women and on genital and plasma HIV viral load
in HIV-positive women. The cohort was followed every
3 months for 12e30 months. Women at each visit were
categorised into users or non-users of contraception.
Pregnancy rates and factors associated with pregnancy
incidence and contraceptive use were measured.
Results Overall 254 of 1305 enrolled women became
pregnant at least once during follow-up (pregnancy rate:
12.0/100 person-years). Younger age, being unmarried,
higher baseline parity and changes in contraceptive
method during follow-up were independently associated
with pregnancy. Having paid sex and being HIV positive
were associated with lower risk of pregnancy. Uptake of
contraception was associated with young age, being
unmarried, occupation, parity and the number and type
of sexual partners.
Conclusions Data on use of contraceptive methods and
risk factors for pregnancy can help to guide decisions on
trial eligibility and the need for additional counselling.
Mandatory reliable contraceptive use in study
participants may be required to reduce pregnancy rates
in studies where pregnancy is contraindicated.
INTRODUCTION
HIV/AIDS continues to be a disease of major public
health importance.1 In sub-Saharan Africa, HIV
incidence is particularly high among women
engaged in occupations where they may receive
payment for sex in order to supplement their
income.2e4 A number of large-scale randomised
controlled trials evaluating the safety and effec-
tiveness of new HIV prevention biological inter-
ventions have recently been completed.5 6 The
target population for many of these trials are HIV-
uninfected women at high risk of HIV in sub-
Saharan Africa. However, the same group of
women targeted for these trials also have high rates
of pregnancy, even those who state at enrolment
that they do not intend to become pregnant for the
trial duration.7e10 Pregnancy is contraindicated
for many new biomedical interventions due to
concerns about fetal safety. Participants who
become pregnant may need to be withdrawn from
the trial, reducing the statistical power to detect an
impact of the intervention.10 It is therefore impor-
tant to identify risk factors for pregnancy in speciﬁc
populations of potential trial participants to help
decide eligibility criteria and to develop pregnancy
prevention strategies for future trials.11
We investigated the pregnancy rate, risk factors
for pregnancy and determinants of contraceptive
use in a randomised controlled trials of herpes
simplex virus (HSV)-suppressive therapy for HIV
prevention in north-western Tanzania.
METHODS
We undertook a cohort analysis of women who
took part in a randomised placebo-controlled trial
of the effects of HSV-suppressive therapy with
acyclovir 400 mg twice daily on HIV incidence in
initially HIV-negative women and on genital and
plasma HIV viral load in HIV-positive women. Full
details of this trial have been published previ-
ously.12 13 Brieﬂy, women aged 16e35 years in 19
communities in north-western Tanzania who
worked in bars and food and hospitality venues
were enrolled between January 2004 and May 2006.
At screening, blood was taken for HSV-2 and HIV
serology. At enrolment, inclusion criteria were
being HSV-2 seropositive, understanding the study
aims, not planning to move in the next 24 months,
a negative pregnancy test, not planning to become
pregnant within the next 24 months, not breast
feeding, no history of epilepsy and willing to attend
mobile clinics. Eligible participants were rando-
mised to receive acyclovir 400 mg twice daily or
placebo and were followed up every 3 months for
12e30 months. Women were enrolled in three
phases: phases 1 and 2 were followed up for
30 months and phase 3 for 12 months. The
intervention showed no signiﬁcant effect on the
HIV-related outcomes.
During each visit, participants were asked about
their sexual behaviour since the last visit, symp-
toms of sexually transmitted infections and were
counselled about risk reduction and family plan-
ning. Women were asked if they thought they
might be pregnant, what method of contraception
they were currently using and, if they were not
receiving contraceptives through another service,
were offered the following contraceptives for free:
combined oral contraceptive (COC), injectable
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depot medroxyprogesterone acetate (Depo-provera) or condoms.
At each visit, the participant was tested for pregnancy if her last
menstrual period (LMP) was late or if she thought she might be
pregnant. Routine pregnancy testing was not done because
women were only seen every 3 months and testing women
whose LMP was more than 4 weeks ago should have detected
most pregnancies and limited the detection of non-viable
chemical pregnancies. Further trial tablets were issued unless the
participant was pregnant or had to stop taking trial tablets for
other reasons in which case participants stayed in follow-up
unless they speciﬁcally asked to withdraw. Voluntary HIV
counselling and testing was offered at every visit.
Ethical approval for the trial was given by the ethics
committees of the Tanzanian Medical Research Coordinating
Committee and the London School of Hygiene and Tropical
Medicine (Current Controlled Trials number ISRCTN35385041).
This study is a secondary analysis of trial data that were
analysed using Stata V.10.1 (College Station). Pregnancy rates
were calculated as number of pregnancies/person-years of
follow-up. Women were censored at the earliest of date of ﬁrst
pregnancy, date last seen or end of study. Women who became
pregnant more than once contributed person-years only to the
time of their ﬁrst pregnancy. Since pregnancy tests were not
done at every visit, it was assumed that the subject was not
pregnant if a test was not performed. Date of conception was
calculated as midway between the date of ﬁrst positive preg-
nancy test and the previous visit date, if this period was #9
months. If the period was over 9 months, then date of concep-
tion was assumed to be 4.5 months before the date of ﬁrst
positive pregnancy test. To check the sensitivity of the results to
the deﬁnition of date of conception, two additional methods
were used to estimate the conception date. First, the conception
date was estimated as 40 weeks before the delivery date, if that
information was available (no pre-term births were recorded in
the trial). Second, the conception date was estimated as midway
between the LMP date of and ﬁrst positive pregnancy test.
Poisson regression was used to estimate RR for the association
of pregnancy with baseline factors and time-varying exposures
measured during follow-up and trends in pregnancy rates over
trial follow-up.
Contraceptive use at each visit was categorised as any modern
method (hormonal methods, the intra-uterine contraceptive
device (IUD) or condoms) or other method. ORs for factors
associated with modern contraception use during follow-up
were estimated using random effects logistic regression to
account for within-woman correlations. The enrolment visit
was excluded from the analysis. Trends over time in the use of
hormonal methods and condoms were assessed, restricted to
women who attended the 30-month visit. Condom use was
deﬁned from responses to the question ‘what method are you
currently using for family planning?’ and did not include
condom use for other purposes.
Women who were surgically sterile at enrolment were
excluded from the pregnancy risk factor analyses (as they were
not at risk of pregnancy) and contraceptive use. They were
included in the calculation of pregnancy rates as they contrib-
uted to the person-years of follow-up.
A conceptual framework was used to build a multivariable
model for factors associated with pregnancy and with modern
contraception.14 Age was considered an a priori confounder.
Baseline socio-demographic factors whose age-adjusted associa-
tion reached p<0.10 were included in an initial multivariable
model and retained if they remained independently associated
with the outcome at p<0.10. Baseline behavioural factors were
added to this model one by one, and those remaining signiﬁcant
at p<0.10 were retained. Associations with time-varying
behavioural factors were determined in a similar way. The ﬁnal
model excluded factors one at a time, starting with the factor
with the largest p value, until all remaining factors were
signiﬁcant at p<0.05.
RESULTS
Socio-demographic and behavioural characteristics at baseline
Overall 1305 women were enrolled, 652 (50.0%) were rando-
mised to acyclovir and 653 to placebo. The mean (SD) age of
participants at screening was 27.6 (4.9) years. Over half the
women (54.3%) were divorced, separated or widowed and 85.7%
had at least one child (table 1). Over half of those enrolled
(54.9%) stated that they wanted to have children in the future.
At enrolment, 54.0% were not using any form of contracep-
tion and 29.6% were using hormonal contraceptives (table 1).
Overall, 37.1% women were HIV positive. Over half (60.3%)
accepted Voluntary HIV counselling and testing and were
informed of their HIV status at enrolment, including 56.4% of
HIV-positive women.
Pregnancy rates and outcomes
During the trial, 254 (19.5%) women became pregnant at least
once, giving a pregnancy rate of 12.0/100 person-years (95% CI
10.6 to 13.6/100 person-years; table 2), and 22 women became
pregnant twice. Pregnancy rates were similar among phases 1 and
2 women enrolled for 30 months (12.0, 95% CI 10.5 to 13.7) and
phase 3 women enrolled for 12 months (12.2, 95% CI 8.5 to 17.5;
table 2). Pregnancy rates were highest in the ﬁrst 3 months of the
trial with weak evidence of a decreasing trend in pregnancy rates
over the study duration (RR for linear trend from 1 year to the
next ¼0.85/year, 95% CI 0.72 to 1.01, p¼0.07; supplemental
ﬁgure 1). HIV-uninfected women had higher pregnancy rates,
particularly in younger age groups (supplemental ﬁgure 1).
Pregnancy rates were similar using the two alternative methods
of estimating the conception date (11.4/100 person-years, 95% CI
10.0 to 12.9 based on delivery dates; 11.8/100 person-years, 95%
CI 10.4 to 13.4 based on LMP). Of the 276 pregnancies, 163
(59.1%) were full-term live births (table 2). The outcomes of 74
(26.8%) pregnancies were not known.
Risk factors for pregnancy
In univariate analysis, factors associated with incident preg-
nancy included younger age, lower education level, being
unmarried, occupation, contraceptive method in the preceding
3 months, changing contraceptive methods between visits,
fewer sexual partners in the past 3 months, not having paid sex
and being HIV uninfected (table 3). Among contraceptive users,
the lowest pregnancy rates were in those using injectable
hormonal contraception (3.68/100 person-years). Pregnancy
rates were similar for condom and COC users (10.21/100 person-
years and 10.77/100 person-years, respectively).
In multivariate analysis, younger age, being single (adjusted
RR (aRR) 1.76, 95% CI 1.18 to 2.64), higher parity and not using
contraception (aRR 5.84, 95% CI 4.31 to 7.91) were indepen-
dently associated with pregnancy (table 3). Having paid sex in
the last 3 months (aRR 0.59, 95% CI 0.43 to 0.81), using
injectable contraception and being HIV positive (aRR 0.55, 95%
CI 0.42 to 0.73) were inversely associated with pregnancy.
Number of children and age were strongly confounded, and the
effect of each of these variables on pregnancy rate was
strengthened after adjusting for the other variable.
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The highest rate of pregnancy was during periods when
women stopped using modern contraception (100.5/100 person-
years). After adjusting for other factors, when women stopped
using modern contraception, they were at 11 times the risk of
pregnancy than when women used modern contraception
without changing method, while during periods when women
used no or non-modern contraception, they were at about four
times the risk of pregnancy (table 3). In contrast, when women
changed between modern contraceptive methods, they were at
lower risk of pregnancy than during periods when there was no
change (aRR¼0.32, 95% CI 0.13 to 0.77). Of the ﬁve pregnancies
that occurred in women changing contraceptive methods, three
became pregnant changing from hormonal methods to
condoms, one when changing from condoms to a hormonal
method and one when changing from injections to COC.
Trends in contraceptive use
Trends in contraceptive use were analysed in 520 women who
completed the study at 30 months without becoming pregnant
and who were not surgically sterilised. There was an increase in
COC use from 11.0% at enrolment to 28.5% at 3 months,
and this remained around 37% after 9 months (supplemental
ﬁgure 2). Injection use increased from 20.6% at enrolment to
32.2% at 9 months but fell slightly thereafter and remained
around 26%. Similarly, condom use as a contraceptive method
increased from 6.5% at enrolment to 23.6% at 3 months, with
little change thereafter.
Factors associated with modern contraceptive use during
follow-up
Young age, being unmarried, occupation at screening, religion,
high parity, living apart from her partner, increasing sexual
partners in the past 3 months, paid sex in the past 3 months and
knowledge of positive HIV status were associated with modern
contraceptive use on univariate analysis (table 4). On multi-
variate analysis, factors independently associated with modern
contraception included younger age, being unmarried (adjusted
OR 7.80, 95% CI 2.83 to 21.52 for single compared with
married), having a regular partner (adjusted OR 2.47, 95% CI
1.19 to 5.13), occupation (highest among bar workers, lowest
among local brew sellers), high parity and increasing sexual
partners in the last 3 months (table 4). Women who were HIV
positive and aware of their status were less likely to use modern
contraception compared with HIV-positive women who were
Table 1 Baseline socio-demographic and behavioural
characteristics of the women in the cohort
N (%)
Socio-demographic characteristics
Age (years)
16e19 71 (5.4)
20e24 289 (22.2)
25e29 424 (32.5)
30e35 521 (39.9)
Educational level
None 153 (11.7)
Incomplete primary 228 (17.5)
Completed primary or higher 924 (70.8)
Marital status
Married/living as married 328 (25.1)
Divorced/separated/widowed 708 (54.3)
Single 269 (20.6)
Occupational group at screening
Local food handler 661 (50.7)
Guesthouse 139 (10.7)
Bar worker 208 (15.9)
Local brew seller 95 (7.3)
Restaurant/cafe/grocery 202 (15.5)
Number of children ever
None 186 (14.3)
1 337 (25.8)
2e4 679 (52.0)
$5 103 (7.9)
Wish to have children in future
No 572 (44.0)
Yes 714 (54.9)
Don’t know 15 (1.1)
Behavioural characteristics
Any regular partner
Yes 1084 (83.1%)
No 221 (16.9%)
Living with partner*
In the same house 343 (26.5)
Apart, meet weekly to <3 monthly 521 (40.2)
Apart, meet >3 monthly 210 (16.2)
No regular partner 221 (17.1)
Number of sexual partners in the last 3 m
0e1 769 (58.9)
2 325 (24.9)
$3 43 (16.2)
Paid sex in the past 3 m
No 806 (61.8)
Yes 499 (38.2)
Contraceptive use at enrolment
None 705 (54.0)
Combined oral contraceptive 144 (11.0)
Injection 243 (18.6)
Condom 91 (7.0)
Rhythm/withdrawal/traditional 74 (5.7)
Intrauterine contraceptive device 6 (0.5)
Surgical sterilisation 42 (3.2)
HIV status at enrolment
Negative 821 (62.9)
Positive 484 (37.1)
*65 missing values.
Table 2 Pregnancy incidence and outcomes
Total number of pregnancies 276
Number of women with 1 pregnancy 232
Number of women with >1 pregnancy 22
Median (IQR) time from enrolment to first pregnancy in years*
All women 0.85 (0.35e1.56)
Women enrolled in phases 1 and 2 (30-month follow-up) 1.04 (0.36e1.60)
Women enrolled in phase 3 (12-month follow-up) 0.42 (0.14e0.68)
Pregnancy incidence during follow-up (per 100 person-years)y
All women 12.0 (10.6e13.6)
Women enrolled in phases 1 and 2 (30-month follow-up) 12.0 (10.5e13.7)
Women enrolled in phase 3 (12-month follow-up) 12.2 (8.5e17.5)
Pregnancy outcome
Term live birth 163 (59.1%)
Premature live birth 0 (e)
Stillbirth 4 (1.4%)
Miscarriage 24 (8.7%)
Termination 10 (3.6%)
Ectopic pregnancy 1 (0.4%)
Unknown 74 (26.8%)
Total 276 (100%)
*Among 254 women who became pregnant at least once.
yIncidence restricted to first pregnancy.
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Table 3 Association between pregnancy and socio-demographic and behavioural factors
Number pregnancies/
person-years
Pregnancy rate/
100 person-years
Unadjusted rate ratio
(95% CI)
Adjusted rate ratio
(95% CI)*
Socio-demographic and behavioural factors at baseline
Age (years) p<0.001 p<0.001
16e19 30/79 38.06 5.55 (3.57 to 8.62) 19.98 (11.47 to 34.82)
20e24 80/404 19.83 2.89 (2.06 to 4.05) 6.13 (4.12 to 9.13)
25e29 86/700 12.28 1.79 (1.28 to 2.50) 3.14 (2.18 to 4.52)
30e35 58/845 6.86 1 1
Educational level p¼0.005 p¼0.11
None 25/239 10.47 1 1
Incomplete primary 61/328 18.60 1.78 (1.12 to 2.83) 1.64 (1.01 to 2.65)
Completed primary/higher 168/1461 11.50 1.10 (0.72 to 1.67) 1.32 (0.85 to 2.03)
Marital status p¼0.01 p¼0.02
Married/living as married 60/532 11.29 1 1
Divorced/separated/widowed 127/1115 11.39 1.01 (0.74 to 1.37) 1.24 (0.91 to 1.69)
Single 67/381 17.58 1.56 (1.10 to 2.21) 1.76 (1.18 to 2.64)
Occupational group at screening p¼0.05 p¼0.22
Local food handler 139/1026 13.55 1 1
Guesthouse 19/185 10.24 0.76 (0.47 to 1.22) 1.19 (0.73 to 1.94)
Bar worker 41/317 12.91 0.95 (0.67 to 1.35) 1.23 (0.85 to 1.79)
Local brew seller 11/182 6.06 0.45 (0.24 to 0.83) 0.62 (0.33 to 1.15)
Restaurant/cafe/grocery 44/318 13.84 1.02 (0.73 to 1.43) 1.22 (0.86 to 1.72)
Number of children ever had p¼0.28 p<0.001
None 31/299 10.37 1 1
1 78/523 14.91 1.44 (0.95 to 2.18) 2.77 (1.77 to 4.34)
2e4 128/1053 12.16 1.17 (0.79 to 1.74) 5.11 (3.14 to 8.31)
$5 17/153 11.09 1.07 (0.59 to 1.93) 8.30 (4.09 to 16.86)
Wish to have children in future p¼0.43 p¼0.38
No 102/875 11.65 1 1
Yes 147/1123 13.09 1.12 (0.87 to 1.45) 0.84 (0.63 to 1.12)
Don’t know 5/25 19.66 1.69 (0.69 to 4.14) 1.31 (0.52 to 3.26)
Any regular partner p¼0.88 p¼0.26
Yes 212/1685 12.58 1 1
No 42/343 12.26 0.97 (0.70 to 1.36) 0.82 (0.57 to 1.16)
Living with partner p¼0.54 p¼0.64
In the same house 60/541 11.10 1 1
Apart, meet weekly 104/818 12.72 1.15 (0.83 to 1.57) 0.93 (0.49 to 1.73)
Apart, meet 3 monthly or less 46/311 14.78 1.33 (0.91 to 1.96) 1.05 (0.56 to 1.99)
No regular partner 42/343 12.26 1.10 (0.74 to 1.64) 0.79 (0.40 to 1.56)
Time varying behavioural factors during follow-up
Current contraceptive method p<0.001 p<0.001
Combined oral contraceptive 83/771 10.77 1 1
Injection 19/516 3.68 0.34 (0.21 to 0.56) 0.29 (0.18 to 0.48)
Condom 49/480 10.21 0.95 (0.67 to 1.35) 1.26 (0.88 to 1.81)
Nothing 100/248 40.26 3.74 (2.79 to 5.00) 5.84 (4.31 to 7.91)
Intrauterine contraceptive device 0/10 e
Sexual partners in the last 3 months p¼0.03 p¼0.96
0e1 193/1407 13.72 1 1
2 41/427 9.59 0.70 (0.50 to 0.98) 0.94 (0.52 to 1.70)
$3 17/193 8.79 0.64 (0.39 to 1.05) 1.00 (0.46 to 2.17)
Paid sex in the past 3 months p¼0.002 p<0.001
No 198/1423 13.92 1 1
Yes 53/605 8.77 0.63 (0.47 to 0.85) 0.59 (0.43 to 0.81)
Current HIV status p<0.001 p<0.001
Negative 180/1197 15.04 1 1
Positive 74/831 8.90 0.59 (0.45 to 0.78) 0.55 (0.42 to 0.73)
HIV positive and aware p¼0.73 p¼0.59y
No 27/319 8.45 1 1
Yes 47/512 9.18 1.09 (0.68 to 1.74) 0.87 (0.54 to 1.42)
HIV negative and aware p¼0.11 p¼0.40y
No 44/356 12.34 1 1
Yes 136/840 16.19 1.31 (0.93 to 1.84) 1.16 (0.82 to 1.63)
Continued
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not aware of their status (adjusted OR¼0.43, 95% CI 0.21
to 0.87).
DISCUSSION
We found an overall pregnancy rate of 12.0/100 person-years
(95% CI 10.6 to 13.6) in HIV prevention trial participants in
Tanzania. HIV-negative women were at increased risk of preg-
nancy (rate¼15.0/100 person-years). The uptake of modern
contraceptives increased following enrolment.
In biomedical HIV prevention trials, women who become
pregnant during the trial are generally withdrawn from investi-
gational product use due to fetal safety concerns and their
observations are censored, as was done in our study. Our results
conﬁrm those of other HIV prevention trials where a high rate of
pregnancy is consistently reported despite offering free contra-
ception services.8 9 11 15 16 Rates in these trials have varied from
around 8/100 to 52/100 person-years.9 15 16 This variation may be
due to differences in fertility, the frequency of pregnancy testing
or sex unprotected by contraceptive methods, availability and
efﬁcacy of contraception used and differences in adherence. We
did not test for pregnancy routinely at every visit unless there
was a suspicion of pregnancy, which may have missed some
pregnancy losses. Conversely frequent pregnancy testing will lead
to an increase in recorded pregnancies because this will identify
chemical pregnancies, which do not become true pregnancies,
and some early pregnancies, which would have been spontane-
ously or medically aborted. In one multicentre trial where preg-
nancy testing was conducted at quarterly intervals, 25.9% of the
228 positive pregnancy tests were negative at the next testing,
presumably due to spontaneous or elective abortions.8
The factors associated with pregnancy in our study are similar
to several previous studies.7 8 16 17 Young Tanzanian women are
who are fertile may avoid the use of hormonal contraception if
they perceive that it could reduce their future chances of
conceiving, as supported by reported preference for using
condoms in young women.18 19 Multiparous women were also
at higher risk of pregnancy, possibly because those who already
have children may be more fertile or may desire to have more.
HIV-uninfected women had higher pregnancy rates than HIV-
infected women, as shown in other studies.20e22 HIV infection
has been associated with reduced fertility.20 21 HIV-infected
women may also be conscious of their health needs and the
potential burden of caring for a child and thus may be more
cautious about becoming pregnant,23 24 although perceived high
risk for HIV was associated with an increased desire for future
pregnancies in Zimbabwe.25 In an HIV prevention trial in
serodiscordant couples, pregnancy rates were similar in HIV-
infected and HIV-uninfected women.26
Women who received payment for sex had lower pregnancy
rates. This may be related to ability to negotiate condom use19
or to higher rates of sexually transmitted infections and their
sequelae, such as pelvic inﬂammatory disease.27 Those with
occasional paying partners may also have fewer total sex acts
than women in regular partnerships.
Just over half of women in this trial were not using any form
of contraceptive at enrolment, similar to studies in Madagascar
and South Africa.16 28 Uptake of condoms for contraception and
hormonal contraception increased as soon as women entered the
trial and contraceptive usage remained fairly stable throughout
the study which suggests that counselling and family planning
provision had an immediate and sustained effect on contracep-
tive practices after study entry. Stopping contraception was, not
unexpectedly, associated with a very high risk of pregnancy.
Women who consistently did not use modern contraceptives
were also at an increased, but lower, risk of pregnancy.
Changes in family planning methods have primarily been
described for women pre- and post-trial enrolment where trial-
speciﬁc family planning counselling can inﬂuence uptake of
condoms for example.29 In our trial, 73% of women changed
contraceptive method at least once during follow-up but,
with the exception of stopping contraception, this was not
associated with a higher pregnancy risk compared with periods
of consistent contraceptive method use.
Study participants who were HIV positive and aware of their
status were less likely to use contraception. This has important
implications for the risk of transmitting the virus to their
partners or children, even if these women are less likely to
become pregnant30e32 and emphasises the importance of
offering free and comprehensive family planning services as part
of standard of care of HIV-infected women.
Women who engage in paid sex may be more likely to use
contraception because they may have one-time relationships,
even if they have regular partners, and becoming pregnant may
reduce their income. As mentioned above, these women may be
able to better negotiate condom use.19 Women with regular
partners were more likely to use modern contraception than
those without regular partners, possibly because the latter are
having less frequent sex or no sex at all. Unlike studies in
developed countries,33 having a higher number of sexual partners
in the past 3 months was associated with using contraception,
which may be related to frequency of sex.
A limitation of our study is that we did not routinely test for
pregnancy at each visit, so we may have underestimated the
pregnancy rate in this cohort. In addition, we did not gather
data on dual contraception method use. Strengths of the study
include a large sample size, with data on current contraceptive
Table 3 Continued
Number pregnancies/
person-years
Pregnancy rate/
100 person-years
Unadjusted rate ratio
(95% CI)
Adjusted rate ratio
(95% CI)*
Change in contraceptive methodz p<0.001 p<0.001x
No change in method (using modern contraception) 136/1417 9.60 1 1
Start modern contraception 10/198 5.04 0.53 (0.28 to 1.00) 0.56 (0.29 to 1.07)
Stop modern contraception 60/60 100.5 10.47 (7.72 to 14.18) 11.16 (8.18 to 15.23)
No change in method (not using modern contraception) 40/188 21.23 2.21 (1.55 to 3.15) 3.67 (2.54 to 5.29)
Using modern contraception, change method 5/162 3.08 0.32 (0.13 to 0.78) 0.32 (0.13 to 0.77)
*Adjusted for independent predictors of pregnancy: age group, marital status, number of children, current contraceptive method, paid sex in the past 3 months and HIV status.
yBoth variables relating to HIV status and knowledge of HIV status included in model at the same time, adjusted for independent predictors of pregnancy listed in first footnote. Shows
association between pregnancy rate and knowledge of HIV status separately among HIV-positive and HIV-negative women.
zContraceptive method reported at current visit compared with that reported at previous visit. Modern contraception defined as combined oral contraceptive (COC), injection, condom or IUCD.
Analysed as a time-updated variable, so distinguishes between periods when women report no change in a particular method (eg, report using COC at current and previous visit), start/stop
using a modern method or change between two modern methods (eg, using COC at current and condom at previous visit).
xAdjusted for all independent predictors of pregnancy listed in first footnote, except for current contraceptive method.
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Table 4 Factors associated with use of modern* contraceptive method during follow-up
No. using modern contraception/visits (%) Unadjusted OR (95% CI) Adjusted OR (95% CI)y
Socio-demographic and behavioural factors at baseline
Age (years) p<0.001 p<0.001
16e19 256/265 (96.6%) 17.98 (2.85 to 113.34) 31.05 (4.56 to 211.21)
20e24 1369/1449 (94.5%) 6.66 (3.19 to 13.87) 8.85 (3.83 to 20.46)
25e29 2363/2583 (91.5%) 4.85 (2.67 to 8.81) 5.51 (2.88 to 10.54)
30e35 2649/3229 (82.0%) 1 1
Educational level p¼0.07 p¼0.20
None 754/885 (85.2%) 1 1
Incomplete primary 1086/1208 (89.9%) 3.08 (1.15 to 8.27) 2.65 (0.96 to 7.26)
Completed primary/higher 4797/5433 (88.3%) 2.14 (0.97 to 4.75) 1.83 (0.82 to 4.10)
Marital status p<0.001 p<0.001
Married/living as married 1691/2018 (83.8%) 1 1
Divorced/separated/widowed 3660/4139 (88.4%) 2.16 (1.19 to 3.93) 1.89 (0.99 to 3.61)
Single 1286/1369 (93.9%) 8.10 (3.43 to 19.13) 7.80 (2.83 to 21.52)
Occupational group at screening p<0.001 p<0.001
Local food handler 3256/3809 (85.5%) 1 1
Guesthouse 620/683 (90.8%) 2.15 (0.87 to 5.31) 2.27 (0.86 to 5.95)
Bar worker 1122/1178 (95.3%) 6.90 (2.94 to 16.22) 4.84 (1.94 to 12.08)
Local brew seller 547/683 (80.1%) 0.41 (0.16 to 1.05) 0.56 (0.22 to 1.38)
Restaurant/cafe/grocery 1092/1173 (93.1%) 4.42 (2.00 to 9.75) 3.70 (1.59 to 8.64)
Religion p¼0.04 p¼0.07
Catholic 3219/3586 (89.8%) 1 1
Protestant 1603/1875 (85.5%) 0.56 (0.30 to 1.04) 0.50 (0.26 to 0.96)
Muslim 1607/1798 (89.4%) 1.22 (0.63 to 2.35) 1.32 (0.67 to 2.63)
Other/none 208/267 (77.9%) 0.21 (0.05 to 0.87) 0.42 (0.11 to 1.64)
Number of children ever had p¼0.02 p<0.001
None 887/1085 (81.8%) 1 1
1 1676/1902 (88.1%) 2.26 (0.99 to 5.16) 3.48 (1.44 to 8.38)
2e4 3561/3944 (90.3%) 3.44 (1.63 to 7.27) 14.78 (6.14 to 35.60)
$5 513/595 (86.2%) 3.69 (1.16 to 11.78) 50.60 (13.54 to 189.13)
Wish to have children in future p¼0.29 p¼0.48
No 2926/3290 (88.9%) 1 1
Yes 3612/4124 (87.6%) 0.63 (0.37 to 1.07) 0.67 (0.36 to 1.25)
Don’t know 86/97 (88.7%) 1.65 (0.11 to 24.50) 1.31 (0.06 to 28.19)
Any regular partner p¼0.19 p¼0.03
Yes 5558/6265 (88.7%) 1.71 (0.88 to 3.35) 2.47 (1.19 to 5.13)
No 1079/1261 (85.6%) 1 1
Living with partner p¼0.001 p¼0.11z
In the same house 1723/2055 (83.8%) 1 1
Apart, meet weekly 2718/3000 (90.6%) 3.00 (1.59 to 5.68) 0.64 (0.20 to 2.06)
Apart, meet 3 monthly or less 1056/1148 (92.0%) 4.90 (2.08 to 11.56) 1.02 (0.28 to 3.71)
No regular partner 1079/1261 (85.6%) 1.33 (0.61 to 2.89) 0.30 (0.08 to 1.10)
Time-varying behavioural factors during follow-up
Sexual partners in the last 3 months p<0.001 p¼0.02
0e1 4484/5205 (86.2%) 1 1
2 1460/1595 (91.5%) 1.76 (1.22 to 2.53) 1.59 (1.10 to 2.29)
$3 693/726 (95.5%) 2.43 (1.32 to 4.47) 1.89 (1.02 to 3.51)
Paid sex in the past 3 months p<0.001 p¼0.10
No 4535/5268 (86.1%) 1 1
Yes 2102/2258 (93.1%) 2.03 (1.44 to 2.86) 1.69 (0.91 to 3.12)
Current HIV status p¼0.46 p¼0.85
Negative 3908/4421 (88.4%) 1 1
Positive 2729/3105 (87.9%) 1.21 (0.74 to 1.96) 1.04 (0.63 to 1.72)
HIV positive and aware p¼0.03 p¼0.02x
No 1052/1178 (89.3%) 1 1
Yes 1677/1927 (87.0%) 0.44 (0.21 to 0.92) 0.43 (0.21 to 0.87)
HIV negative and aware p¼0.28 p¼0.46x
No 1220/1346 (90.6%) 1 1
Yes 2688/3075 (87.4%) 0.71 (0.38 to 1.33) 0.77 (0.41 to 1.45)
*Modern contraception defined as any hormonal method, IUCD or condoms.
yAdjusted for independent predictors of using contraception: age group, marital status, occupational group at screening, number of children, any regular partner and number of partners in the
past 3 months.
zAdjusted for all independent predictors of using contraception listed in second footnote, except for any regular partner.
xBoth variables relating to HIV status and knowledge of HIV status included in the model at the same time, adjusted for independent predictors of using contraception listed in second footnote.
Shows association between using modern contraception and knowledge of HIV status separately among HIV-positive and HIV-negative women.
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use gathered at 3-month intervals allowing us to look at the
effect of changing contraceptive methods.
In conclusion, this study demonstrated a high incidence of
pregnancy in an HIV prevention trial cohort and identiﬁed
a number of factors that predict increased risk of pregnancy and
use of effective modern contraceptives following study enrol-
ment. Such information may be of value in selecting partici-
pants for future trials where pregnancy is contraindicated or
identifying the need for more intensive counselling to explain
that pregnancy may result in study withdrawal, in addition to
family planning provision targeted to women who are at highest
risk of pregnancy. Where it is essential to minimise pregnancy in
study participants, mandatory use of an effective contraceptive
method such as hormonal method or IUDs, alongside condoms
for HIV prevention, would be the only approach likely to
achieve this since self-reported pregnancy intentions are not
reﬂected in actual pregnancy rates in many trials. However,
recent ﬁndings have shown that hormonal contraception may
increase the risk of HIV acquisition in HIV-negative women and
female-to-male HIV transmission, although results from studies
have not always been consistent and may depend on age and
type of hormonal contraception.34e38 Further studies are
urgently needed to determine which speciﬁc hormonal methods
and which dose of hormone may be recommended in popula-
tions at risk of HIV. Until then, clear counselling about the
potential risks and beneﬁts of hormonal contraception, offering
alternative contraceptive choices, such as IUD, and on-going
condom promotion and provision will be essential when offering
contraception for HIV prevention trial participants.
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